HIGHLIGHTS
First quarter of 2022 was strong. In aggregate, strategic brands grew 25% in the first quarter of 2022 reaching
EBIT reached
Strategic brand performance:
- Revenue of Brintellix®/Trintellix®:
DKK 990 million (+23%). -
Revenue of Rexulti®/Rxulti®:
DKK 831 million (+24%). -
Revenue of Abilify Maintena®:
DKK 677 million (+16%). -
Revenue of Vyepti®:
DKK 170 million (+124%).
- Revenue of Brintellix®/Trintellix®:
Market performance:
- Revenue in
the United States :DKK 1,918 million (down 1%). -
Revenue in International Markets:
DKK 1,456 million (+16%). -
Revenue in
Europe :DKK 1,022 million (+11%).
- Revenue in
Outlook 2022 maintained
- Revenue expected at
DKK 16.7 - 17.3 billion. -
Core EBIT expected at
DKK 3.6 - 4.0 billion. -
EBIT expected at
DKK 2.2 - 2.6 billion.
In connection with the quarterly corporate release, Lundbeck's President and CEO,
"Lundbeck continues to deliver robust financial performance with its strong portfolio of brands. Vyepti is growing as the pandemic impact on face-to-face interactions diminishes. We are delighted with the new data from the VIVRE study comparing Brintellix/Trintellix to desvenlafaxine, further strengthening its profile as a great choice for people facing depression. Our pipeline continues to progress, and we look forward to important clinical data readouts from ongoing studies with Rexulti, Vyepti and our early-stage projects in the coming quarters."
Key figures:
DKK million | Q1 2022 | Q1 2021 | Growth |
Core Revenue* | 4,372 | 4,273 | 2% |
Core EBIT* | 1,184 | 1,253 | (6%) |
Core EPS* (DKK) | 4.67 | 4.65 | - |
Core EBIT margin* | 27.1% | 29.3% | |
Reported Revenue | 4,372 | 4,273 | 2% |
Reported EBIT | 875 | 882 | (1%) |
Reported EPS (DKK) | 2.07 | 3.13 | (34%) |
Reported EBIT margin | 20.0% | 20.6% |
*For definition of the measures "Core Revenue", "Core EBIT", "Core EBIT margin" and "Core EPS", see note 4 Core reporting
The newest product in the portfolio, Vyepti, continues to grow, reaching
The last patients have been enrolled in the phase III study of brexpiprazole in patients facing Agitation in Alzheimer's Disease, thus on track for headline results by mid-2022.
The early-stage pipeline is also progressing as planned. The first subject was dosed in Single-Ascending Dose (SAD) phase I study with Lu AG22515 (CD40L inhibitor).
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/focus-on-strategic-brands-continues-to-ensure-solid-operational-performance-in-q1-2022,c3564711
https://mb.cision.com/Main/18215/3564711/1577891.pdf
(c) 2022 Cision. All rights reserved., source